FX 909
Alternative Names: FTX-6746; FX-909Latest Information Update: 03 Nov 2025
At a glance
- Originator Flare Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor gamma antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Urogenital cancer
Most Recent Events
- 24 Oct 2025 Efficacy, adverse events, pharmacodynamics and pharmacokinetics data from phase I clinical trial in Urogenital cancer released by Flare Therapeutics
- 22 Oct 2025 Efficacy, adverse events, pharmacokinetics and pharmacokinetics data from the phase I trial in Urogenital cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025
- 14 Oct 2025 Flare Therapeutics plans a phase II trial for Urogenital cancer